14,260,800 Shares of Common Stock CTI BIOPHARMA CORP. UNDERWRITING AGREEMENT March 31, 2021Underwriting Agreement • April 6th, 2021 • Cti Biopharma Corp • Pharmaceutical preparations • New York
CTI BioPharma Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule I hereto (the “Underwriters”) for whom you are acting as representatives (the “Representative”) (i) an aggregate of 14,260,800 shares (the “Common Shares”) of the common stock, par value $0.001 per share, of the Company (“Common Stock”) and (ii) an aggregate of 600 shares (the “Preferred Shares” and, together with the Common Shares, the “Firm Shares”) of the Series X1 Preferred Stock, par value $0.001 per share, of the Company (the “Preferred Stock”). The Company also proposes to sell to the several Underwriters at the option of the Underwriters, up to an additional 2,139,120 shares of Common Stock (the “Option Shares”). The Firm Shares and the Option Shares are hereinafter referred to collectively as the “Shares.”
